Alvotech (ICE:ALVO)

Iceland flag Iceland · Delayed Price · Currency is ISK
1,010.00
-10.00 (-0.98%)
At close: Oct 24, 2025
-0.98%
Market Cap312.71B
Revenue (ttm)68.10B
Net Income (ttm)7.67B
Shares Outn/a
EPS (ttm)26.33
PE Ratio40.77
Forward PE18.04
Dividendn/a
Ex-Dividend Daten/a
Volume530,621
Average Volume146,378
Open1,015.00
Previous Close1,020.00
Day's Range1,000.00 - 1,020.00
52-Week Range946.00 - 1,945.00
Beta0.10
RSI49.88
Earnings DateNov 12, 2025

About Alvotech

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company’s lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory cond... [Read more]

Sector Healthcare
Founded 2013
Employees 1,012
Stock Exchange Nasdaq Iceland
Ticker Symbol ALVO
Full Company Profile

Financial Performance

In 2024, Alvotech's revenue was $491.98 million, an increase of 426.84% compared to the previous year's $93.38 million. Losses were -$231.86 million, -57.98% less than in 2023.

Financial numbers in USD Financial Statements

News

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

REYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

6 days ago - GlobeNewsWire

Alvotech Announces Changes in Global Business Development and Commercial Operations Team

REYKJAVIK, ICELAND (OCTOBER 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announce...

6 days ago - GlobeNewsWire

Alvotech: Promising Vertically Integrated Biosimilar Platform

Alvotech is a vertically integrated biosimilar pure-play. In my view, this makes it a relatively safer bet compared to other, more speculative biotechs. ALVO plans on launching adalimumab and ustekinu...

13 days ago - Seeking Alpha

My Top 5 Biotech Stocks Big Pharma Could Buy Next

While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...

21 days ago - Seeking Alpha

European Marketing Application for AVT23, a Proposed Biosimilar to Xolair® (omalizumab), Accepted by the European Medicines Agency

LONDON, UK and  REYKJAVIK, ICELAND (OCTOBER 6, 2025) — Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global pharmaceutical company with a strategic focus on specialty, hospital, a...

22 days ago - GlobeNewsWire

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

5 weeks ago - GlobeNewsWire

European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech's Proposed Biosimilar to Prolia® and Xgeva®

REYKJAVIK,  ICELAND (September 22, 2024) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today annou...

5 weeks ago - GlobeNewsWire

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...

5 weeks ago - GlobeNewsWire

European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech's Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner

REYKJAVIK,  ICELAND and LONDON, UK (September 22, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwi...

5 weeks ago - GlobeNewsWire

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK, Iceland, Sept. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

5 weeks ago - GlobeNewsWire

Alvotech Announces Marketing Approval in Japan of Three New Biosimilars

REYKJAVIK,  ICELAND (September 19, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today annou...

5 weeks ago - GlobeNewsWire

Alvotech (ALVO) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript

Alvotech (NASDAQ:ALVO) Morgan Stanley 23rd Annual Global Healthcare Conference September 10, 2025 10:45 AM EDT Company Participants Balaji Prasad - Chief Strategy Officer Conference Call Participants...

6 weeks ago - Seeking Alpha

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

REYKJAVIK, Iceland, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,...

7 weeks ago - GlobeNewsWire

Alvotech Meets Investors and Participates in a Fireside Chat at the Morgan Stanley 23rd Annual Global Healthcare Conference in New York

REYKJAVIK, Iceland,  June 4, 2025 - Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today it...

7 weeks ago - GlobeNewsWire

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

REYKJAVIK, Iceland and LONDON, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients ...

2 months ago - GlobeNewsWire

Advanz Pharma and Alvotech receive European approval for Mynzepli®, Biosimilar to Eylea®

REYKJAVIK, ICELAND and LONDON, UK (August 21, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide a...

2 months ago - GlobeNewsWire

Alvotech appoints Patrik Ling as VP of Investor Relations Scandinavia

REYKJAVIK,  ICELAND (August 20, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announce...

2 months ago - GlobeNewsWire

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

Alvotech (ALVO) Q2 2025 Earnings Call Transcript

2 months ago - Seeking Alpha

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

REYKJAVIK, Iceland, August 13, 2025 - Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide...

2 months ago - GlobeNewsWire

Alvotech Reports Results for the First Six Months of 2025 and Provides a Business Update

REYKJAVIK, Iceland, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, or the “Company”), a global biotech company specializing in the development and manufacture of biosimilar medicines for pa...

2 months ago - GlobeNewsWire

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

REYKJAVIK, ICELAND (August 6, 2025) – Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today t...

2 months ago - GlobeNewsWire

Alvotech Announces Webcast to Report Financial Results for the First Half of 2025 on August 14, 2025, at 8:00 am EDT

REYKJAVIK, Iceland, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, a...

2 months ago - GlobeNewsWire

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

REYKJAVIK,  ICELAND (July 10, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced ...

3 months ago - GlobeNewsWire

Alvotech Appoints Linda Jónsdóttir as Chief Financial Officer

REYKJAVIK, Iceland, July 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, ...

3 months ago - GlobeNewsWire

Alvotech Expands its Capacity in Assembly and Packaging with the Acquisition of Ivers-Lee Group in Switzerland

REYKJAVIK,  ICELAND AND BURGDORF, SWITZERLAND (JULY 9, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients wo...

3 months ago - GlobeNewsWire